// App-Quantinova.ai

1195 : SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma

Researchers

Presenter

  • Tim Lewis

Principal Investigators

  • Devra J. Olson

  • Kristine A. Gordon

  • Sharsti L. Sandall

  • Jamie Miyamoto

  • Lori Westendorf

  • Germein Linares

  • Chris Leiske

  • Heather Kostner

  • Ivan Stone

  • Martha Anderson

  • Albina Nesterova

  • Mechthild Jonas

  • Che-Leung Law

Medical Centers

  • Seattle Genetics, Bothell, WA

Locations

  • United States

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hematological malignancies

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Multiple Myeloma

  • Hodgkin's Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Apparent diffusion coefficient

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Cysteine Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved